Key Points
- Insider sales: CEO Da Silva Jorge Santos sold 70,000 shares on Dec. 9 at an average $14.49 for $1,014,300 and also sold 130,000 shares on Dec. 8 at $15.08 for $1,960,400, cutting his stake by 2.37% to 2,878,577 shares valued at about $41.7M.
- Company outlook: MoonLake is a clinical‑stage biopharma with a market cap of ~$938.4M, reported Q3 EPS of -$1.10 (missed estimates), holds a consensus "Hold" with a $30.25 target, and has a wide 52‑week range of $5.95–$62.75.
- Institutional activity: Large managers including Nuveen, Two Sigma, Schonfeld, Vestal Point and Balyasny have built positions, and institutional investors now own roughly 93.85% of the stock.
MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) CEO Da Silva Jorge Santos sold 70,000 shares of the business's stock in a transaction dated Tuesday, December 9th. The stock was sold at an average price of $14.49, for a total transaction of $1,014,300.00. Following the completion of the transaction, the chief executive officer directly owned 2,878,577 shares in the company, valued at $41,710,580.73. This trade represents a 2.37% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.
Da Silva Jorge Santos also recently made the following trade(s):
- On Monday, December 8th, Da Silva Jorge Santos sold 130,000 shares of MoonLake Immunotherapeutics stock. The stock was sold at an average price of $15.08, for a total transaction of $1,960,400.00.
MoonLake Immunotherapeutics Stock Performance
Shares of MLTX stock opened at $14.61 on Thursday. The company has a debt-to-equity ratio of 0.25, a quick ratio of 8.50 and a current ratio of 8.50. The firm has a market cap of $938.40 million, a price-to-earnings ratio of -4.40 and a beta of 1.21. MoonLake Immunotherapeutics has a 52 week low of $5.95 and a 52 week high of $62.75. The firm's 50-day simple moving average is $11.36 and its two-hundred day simple moving average is $36.10.
MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) last released its earnings results on Wednesday, November 5th. The company reported ($1.10) earnings per share for the quarter, missing analysts' consensus estimates of ($0.89) by ($0.21). During the same quarter in the previous year, the company earned ($0.56) EPS. As a group, equities analysts forecast that MoonLake Immunotherapeutics will post -1.79 earnings per share for the current year.
Hedge Funds Weigh In On MoonLake Immunotherapeutics
Hedge funds have recently bought and sold shares of the company. Schonfeld Strategic Advisors LLC purchased a new position in shares of MoonLake Immunotherapeutics during the third quarter worth approximately $6,922,000. Nuveen LLC bought a new position in shares of MoonLake Immunotherapeutics during the 1st quarter valued at $26,308,000. Two Sigma Investments LP bought a new position in shares of MoonLake Immunotherapeutics during the 3rd quarter valued at $3,257,000. Vestal Point Capital LP raised its position in MoonLake Immunotherapeutics by 175.0% in the 2nd quarter. Vestal Point Capital LP now owns 550,000 shares of the company's stock worth $25,960,000 after purchasing an additional 350,000 shares during the period. Finally, Balyasny Asset Management L.P. lifted its stake in MoonLake Immunotherapeutics by 436.8% in the second quarter. Balyasny Asset Management L.P. now owns 423,170 shares of the company's stock worth $19,974,000 after purchasing an additional 344,335 shares during the last quarter. Hedge funds and other institutional investors own 93.85% of the company's stock.
Analysts Set New Price Targets
A number of research firms have issued reports on MLTX. Citigroup downgraded MoonLake Immunotherapeutics from a "neutral" rating to a "sell" rating in a research report on Wednesday, October 29th. HC Wainwright decreased their price objective on MoonLake Immunotherapeutics from $30.00 to $26.00 and set a "buy" rating for the company in a report on Friday, November 21st. Stifel Nicolaus cut MoonLake Immunotherapeutics from a "buy" rating to a "hold" rating and set a $13.00 price objective on the stock. in a research note on Monday, September 29th. Wolfe Research downgraded shares of MoonLake Immunotherapeutics from an "outperform" rating to an "underperform" rating in a report on Tuesday, September 30th. Finally, Needham & Company LLC reduced their target price on shares of MoonLake Immunotherapeutics from $66.00 to $20.00 and set a "buy" rating for the company in a research note on Tuesday, September 30th. Five investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and three have given a Sell rating to the company's stock. According to data from MarketBeat, MoonLake Immunotherapeutics has a consensus rating of "Hold" and a consensus price target of $30.25.
Check Out Our Latest Stock Analysis on MLTX
MoonLake Immunotherapeutics Company Profile
(
Get Free Report)
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
